U.S. Gastroparesis Treatment Market Size, Share & Forecast 2026–2032

ID: MR-11692 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Gastroparesis Treatment Market
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 1.71 billion
  • ✓CAGR: 5.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Generic Metoclopramide Dependence Persists: Generic metoclopramide tablets from Teva, Viatris and Hikma still dominate U.S. prescriptions despite the FDA's 2009 tardive dyskinesia boxed warning. Evoke Pharma's Gimoti nasal spray, approved in 2020, is the only branded route gaining share by bypassing the oral tablet's systemic exposure profile.
FINDING 02
Gastric Stimulation Stays Niche: The consensus treats gastric electrical stimulation as the next growth engine, but Medtronic's Enterra system remains a niche therapy. Its Humanitarian Device Exemption carries an annual distribution cap of 8,000 devices, and Medicare coverage depends on documented pharmacological failure, which keeps implant volumes narrow through 2032.
ANALYST RECOMMENDATION

Analyst Recommendation — Prioritise Adherence-Focused Formulations: Specialty pharmaceutical investors should by Q4 2026 evaluate in-licensing of differentiated metoclopramide formulations, because Medicare Part D's USD 2,000 annual out-of-pocket cap, effective January 2025 under the Inflation Reduction Act, shifts adherence economics toward branded products with patient support programmes.

Gastroparesis Treatment in the U.S.: Market Overview

The U.S. gastroparesis treatment market is valued at USD 1.12 billion in 2024 and remains anchored by generic metoclopramide, prescribed under the FDA-approved Reglan label for diabetic and idiopathic delayed gastric emptying. The FDA's 2009 boxed warning for tardive dyskinesia, followed by labelling that restricts treatment duration, pushed prescribing toward shorter courses and created a large generic substitution base supplied by Teva, Viatris and Hikma.

Government has led evidence generation. The National Institute of Diabetes and Digestive and Kidney Diseases funds the Gastroparesis Clinical Research Consortium, whose validation studies underpin symptom endpoints used in regulatory submissions. Private companies have led commercialisation, including Evoke Pharma's Gimoti nasal spray, approved in 2020, and Medtronic's Enterra gastric electrical stimulation system, cleared through a Humanitarian Device Exemption in 2000.

Policy-Driven Growth in U.S. Gastroparesis Treatment

The Inflation Reduction Act of 2022 is the most consequential demand-side measure. Its Medicare Part D out-of-pocket cap of USD 2,000 per year, effective January 1, 2025, removes cost barriers for Medicare beneficiaries, who make up a large share of chronic gastroparesis patients. Continuous prescription fills rise as patients stop rationing doses at the pharmacy counter.

The 21st Century Cures Act of 2016 amended the Humanitarian Device Exemption under section 520(m) of the Federal Food, Drug, and Cosmetic Act, allowing sponsors to earn returns on HDE-approved devices such as Enterra. Hatch-Waxman Act generic entry rules of 1984 keep metoclopramide priced at generic levels, so volume growth in oral therapy translates directly into prescription revenue for generic manufacturers.

Regulatory Barriers and Compliance Costs

Gastric electrical stimulation faces the tightest barriers. Under the HDE pathway administered by FDA's Center for Devices and Radiological Health, annual distribution is capped at 8,000 devices. Medicare coverage requires implantation at facilities with institutional review board oversight and documented failure of pharmacological therapy, which delays patient access and raises per-case administrative costs for hospitals.

Pharmaceutical entrants must file New Drug Applications under section 505 of the FD&C Act, with FDA's Division of Gastroenterology and Inborn Errors Products assessing symptom endpoints. Unapproved domperidone remains restricted by FDA import controls issued after 2014 cardiac safety warnings. Physicians are therefore channelled toward FDA-approved metoclopramide, which carries the tardive dyskinesia boxed warning and limits branded uptake.

Policy-Created Opportunities in U.S. Gastroparesis Care

CMS's Transitional Coverage for Emerging Technologies pathway, finalised in 2024, grants breakthrough devices provisional Medicare coverage while evidence is collected. This creates an entry route for next-generation gastric stimulators and sensor-based pacing systems. FDA's Breakthrough Devices Program, established following the 21st Century Cures Act, provides priority review for qualifying devices in this category.

The Part D redesign under the Inflation Reduction Act rewards formulation innovation. Orally disintegrating and intranasal products that improve adherence within the USD 2,000 cap create branded differentiation against low-cost generics. Companies that secure Part D formulary placement for these formats capture share as beneficiaries move between plan tiers.

Market at a Glance

MetricDetail
Market Size 2024USD 1.12 billion
Market Size 2032USD 1.71 billion
Growth Rate (CAGR)5.4%
Most Critical Decision FactorMedicare Part D formulary placement and coverage criteria
Largest RegionNortheast United States
Competitive StructureConsolidated generics with fragmented branded and device niches

Leading Market Participants

  • Medtronic
  • Evoke Pharma
  • ANI Pharmaceuticals
  • Teva Pharmaceuticals
  • Viatris
  • Vanda Pharmaceuticals
  • Hikma Pharmaceuticals
  • Par Pharmaceutical
  • Amneal Pharmaceuticals
  • Sandoz

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the U.S. Food and Drug Administration. Drugs follow the section 505 New Drug Application route or the Abbreviated New Drug Application route created by the Hatch-Waxman Act of 1984. Devices follow premarket approval or the HDE pathway under section 520(m) through CDRH. Medicare coverage is set by the Centers for Medicare and Medicaid Services under Title XVIII of the Social Security Act, and post-marketing safety reporting follows 21 CFR Part 314.80.

Key upcoming changes include CMS's third cycle of Medicare Drug Price Negotiation, with drug selection due by February 1, 2026 for prices effective in 2028, which will reprice any selected branded gastroparesis agent. Compared with peers, the U.S. framework is more permissive for devices through HDE and TCET. The EU Medical Device Regulation, Regulation (EU) 2017/745, extends legacy device transition to 2027 and imposes stricter clinical evidence requirements. Health Canada's Special Access Programme continues to supply domperidone, which the U.S. restricts.

Long-Term Policy Outlook for Gastroparesis Treatment

By 2032, Medicare price negotiation will reshape branded gastroparesis economics, while generic metoclopramide prices will remain under pressure from multiple Hatch-Waxman filers. CMS is expected to expand TCET-eligible device categories, and Medicare coverage criteria for gastric electrical stimulation will be tested against broader pharmacological failure definitions. These changes will determine which device and branded pathways reach scale.

The market will shift toward branded intranasal and orally disintegrating formulations that perform within Part D's out-of-pocket cap. Device volumes will rise gradually under HDE and TCET conditions rather than through broad coverage expansion. Government-funded research through NIDDK will continue to set the evidence standards that determine which products earn reimbursement, keeping the 5.4% CAGR tied to regulatory milestones.

Frequently Asked Questions

The FDA regulates drugs through the Center for Drug Evaluation and Research and devices through the Center for Devices and Radiological Health. Both operate under the Federal Food, Drug, and Cosmetic Act.
The HDE under section 520(m) allows approval of devices for conditions affecting fewer than 8,000 U.S. patients per year. Enterra was approved under this pathway, and its annual distribution cap limits implant volumes.
The Act caps Medicare Part D out-of-pocket spending at USD 2,000 per year from January 2025. This reduces cost barriers for beneficiaries who need continuous prescriptions.
FDA has not approved domperidone for U.S. use and restricts its importation following cardiac safety warnings. Clinicians therefore rely on FDA-approved metoclopramide and on branded alternatives.
Prescribers must observe the tardive dyskinesia boxed warning and the labelled limit on treatment duration. Manufacturers must report adverse events under 21 CFR Part 314.80.

Market Segmentation

By Therapy Type
  • Prokinetic Agents
  • Antiemetics
  • Gastric Electrical Stimulation
  • Dietary and Nutritional Management
  • Others
By Route of Administration
  • Oral Tablets
  • Orally Disintegrating Tablets
  • Intranasal Spray
  • Implantable Devices
  • Others
By End User
  • Hospitals
  • Retail Pharmacies
  • Specialty Gastroenterology Clinics
  • Mail-Order Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Gastroparesis Treatment - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Therapy Type Insights
4.1 Prokinetic Agents
4.2 Antiemetics
4.3 Gastric Electrical Stimulation
4.4 Dietary and Nutritional Management
4.5 Others
Chapter 05 Route of Administration Insights
5.1 Oral Tablets
5.2 Orally Disintegrating Tablets
5.3 Intranasal Spray
5.4 Implantable Devices
5.5 Others
Chapter 06 End User Insights
6.1 Hospitals
6.2 Retail Pharmacies
6.3 Specialty Gastroenterology Clinics
6.4 Mail-Order Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Medtronic
7.2.2 Evoke Pharma
7.2.3 ANI Pharmaceuticals
7.2.4 Teva Pharmaceuticals
7.2.5 Viatris
7.2.6 Vanda Pharmaceuticals
7.2.7 Hikma Pharmaceuticals
7.2.8 Par Pharmaceutical
7.2.9 Amneal Pharmaceuticals
7.2.10 Sandoz
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.